What Is the Impact of Late-Onset Cytomegalovirus Disease After Valganciclovir Prophylaxis in Kidney Transplantation?

被引：9
|
作者：
Lamoth, Frederic [1 ,2 ,3 ]
Manuel, Oriol [1 ,2 ,3 ]
Venetz, Jean-Pierre [2 ,3 ]
Faouzi, Mohamed [2 ,4 ]
Meylan, Pascal [1 ,2 ,5 ]
Pascual, Manuel [2 ,3 ]
机构：
[1] CHU Vaudois, Infect Dis Serv, Dept Med, CH-1011 Lausanne, Switzerland
[2] Univ Lausanne, CH-1015 Lausanne, Switzerland
[3] CHU Vaudois, Transplantat Ctr, CH-1011 Lausanne, Switzerland
[4] CHU Vaudois, Inst Social & Prevent Med, Ctr Clin Epidemiol, CH-1011 Lausanne, Switzerland
[5] CHU Vaudois, Inst Microbiol, CH-1011 Lausanne, Switzerland
来源：
TRANSPLANTATION | 2008年 / 86卷 / 09期
关键词：
D O I：
10.1097/TP.0b013e3181890788
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：1323 / 1324
页数：2
相关论文
共 50 条
  • [21] Cytomegalovirus-specific cell-mediated immunity after prophylaxis predicts late-onset infection in lung transplantation
    Revilla Lopez, Eva
    Jarque, Marta
    Saez Gimenez, Berta
    Los Arcos, Ibai
    Gomez Olles, Susana
    Bestard, Oriol
    Bravo, Carlos
    Monforte, Victor
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [22] Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation
    Reischig, T.
    Jindra, P.
    Hes, O.
    Svecova, M.
    Klaboch, J.
    Treska, V.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 (01) : 69 - 77
  • [23] Risk Factors for Late-Onset Cytomegalovirus Infection or Disease in Kidney Transplant Recipients
    Jamal, Alainna J.
    Husain, Shahid
    Li, Yanhong
    Famure, Olusegun
    Kim, S. Joseph
    [J]. TRANSPLANTATION, 2014, 97 (05) : 569 - 575
  • [24] De Novo Use of Everolimus Reduces Late-Onset Cytomegalovirus Primary Disease Occurring After Antiviral Prophylaxis Discontinuation in Kidney Transplant Recipients
    Devresse, A.
    Avettand-Fenoel, V.
    Scemla, A.
    Morin, L.
    Lebreton, X.
    Tinel, C.
    Amrouche, L.
    Lamhaut, L.
    Timsit, M. -O.
    Zuber, J.
    Legendre, C.
    Anglicheau, D.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 232 - 232
  • [25] VALGANCICLOVIR PROPHYLAXIS - WHAT IS THE IMPACT?
    Vesey, Alex
    Griffin, Emma
    Aitken, Emma
    MacLean, Catherine
    Black, Heather
    Clancy, Marc
    Jardine, Alan
    Geddes, Colin
    [J]. TRANSPLANT INTERNATIONAL, 2013, 26 : 165 - 165
  • [26] A case report of late-onset gastrointestinal cytomegalovirus infection 17 years post kidney transplantation
    Anupama, Sneha Haridas
    Koshy, Priyanka
    Saraswathy, Arun Ramaswamy
    Parthasarathy, Rajeevalochana
    Mathew, Milly
    Abraham, Georgi
    [J]. INDIAN JOURNAL OF TRANSPLANTATION, 2020, 14 (03) : 263 - 265
  • [27] CYTOMEGALOVIRUS DISEASE OF LATE-ONSET FOLLOWING RENAL-TRANSPLANTATION - A POTENTIALLY FATAL ENTITY
    BOEHLER, A
    SCHAFFNER, A
    SALOMON, F
    KEUSCH, G
    [J]. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1994, 26 (04) : 369 - 373
  • [28] Low-dose valganciclovir is efficacious and safe for prophylaxis of cytomegalovirus infection in kidney transplantation
    Perrottet, Nancy
    Manuel, Oriol
    Venetz, Jean-Pierre
    Lamoth, Frederic
    Decosterd, Laurent A.
    Buclin, Thierry
    Biollaz, Jerome
    Meylan, Pascal
    Pascual, Manuel
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 565 - 566
  • [29] Targeted Prophylaxis to Prevent Late-Onset Pneumocystis jirovecii Pneumonia in Kidney Transplantation: Are We There Yet?
    Cervera, Carlos
    Yaskina, Maryna
    Kabbani, Dima
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 73 (07) : E1464 - E1466
  • [30] VALGANCICLOVIR UNIVERSAL PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION IN HEART TRANSPLANTATION
    Vymetalova, Jevgenija
    Skalicka, Blanka
    Gazdic, Tomas
    Vrbska, Jana
    Malek, Ivan
    [J]. TRANSPLANT INTERNATIONAL, 2009, 22 : 137 - 137
12345